comparemela.com

Latest Breaking News On - Ascendis pharma chart - Page 1 : comparemela.com

United Kingdom s MHRA Approves YORVIPATH (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism Seite 1

24.04.2024 - COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH . Seite 1

United kingdomGreat britainAscendis pharmaRegulatory agencyCamilla harder harvigExecutive vice presidentChief commercial officerAscendis pharma chartScendis pharma kursScendis pharma aktie

Ascendis Presents Updated and New TransCon IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023

26.10.2023 - Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy TransCon IL-2 β⁄γ administered every . Seite 1

Stina singelAscendis pharmaHead of clinical developmentEuropean society of medical oncologyBelieve trialEuropean societyMedical oncologyExecutive vice presidentClinical developmentAscendis pharma chartScendis pharma kursScendis pharma aktie

Ascendis Presents TransCon PTH Data at the American Thyroid Association Annual Meeting

02.10.2023 - – At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maintaining normocalcemia following treatment with . Seite 1

United statesAscendis pharmaAimee shuEuropean unionAmerican thyroid associationEndocrinology medical sciences at ascendis pharmaClinical developmentVice presidentEndocrinology medical sciencesAscendis pharma chartScendis pharma kursScendis pharma aktie

Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023

15.08.2023 - COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday, September 5, 2023, after the close of the U.S. . Seite 1

Ascendis pharmaAscendis pharma chartScendis pharma kursScendis pharma aktie

vimarsana © 2020. All Rights Reserved.